object
respiratori
syncyti
viru
rsv
caus
respiratori
infect
across
world
infant
elderli
particular
risk
develop
sever
diseas
death
replicationdefect
chimpanze
adenoviru
modifi
vaccinia
viru
ankara
mvarsv
vaccin
shown
safe
immunogen
young
healthi
adult
report
extens
firstinman
vaccin
trial
includ
healthi
older
adult
age
year
method
evalu
safeti
immunogen
singl
dose
mvarsv
given
intramuscular
im
inject
n
two
dose
im
given
apart
n
im
prime
im
mvarsv
boost
later
n
intranas
spray
prime
im
mvarsv
boost
later
n
vaccin
n
safeti
measur
includ
advers
event
within
one
week
vaccin
blood
monitor
immunogen
measur
includ
serum
antibodi
respons
rsvand
antibodi
titr
measur
plaquereduct
neutralis
seap
assay
respect
peripher
bcell
immun
respons
frequenc
fspecif
igg
iga
antibodi
secret
cell
memori
bcell
ex
vivo
cultur
dualcolour
elispot
assay
respect
peripher
rsvspecif
tcell
immun
respons
frequenc
ifn
produc
tcell
ex
vivo
elispot
tfhlike
cell
frequenc
icsfac
assay
result
vaccin
safe
well
toler
compar
individu
baselin
immun
mean
foldchang
serum
rsvneutralis
antibodi
appear
magnitud
fspecif
igg
iga
asc
expans
ifn
produc
tcell
peripher
circul
compar
result
seen
younger
healthi
adult
receiv
vaccin
combin
dose
littleno
iga
memori
bcell
respons
younger
older
adult
expans
ifn
tcell
mark
older
adult
follow
im
prime
balanc
cell
respons
rsvspecif
immun
respons
vaccin
appear
attenu
presenc
vector
neutralis
antibodi
conclus
mvarsv
safe
immunogen
older
adult
parallel
induct
rsvspecif
humor
cellular
immun
merit
assess
provid
protect
sever
diseas
human
respiratori
syncyti
viru
rsv
global
distribut
pathogen
caus
respiratori
infect
throughout
life
infant
adult
sever
immunecompromis
elderli
especi
risk
sever
lowerrespiratori
tract
diseas
death
infect
rate
elderli
live
commun
care
home
rang
year
broadli
compar
infect
rate
observ
younger
adult
greatest
oldest
member
elderli
popul
elderli
differ
younger
adult
greater
risk
diseas
progress
lowerrespiratori
tract
caus
respiratori
failur
death
rsv
infect
respons
signific
proport
elderli
hospitalis
pneumonia
chronic
obstruct
pulmonari
diseas
congest
cardiac
failur
asthma
allcaus
mortal
rate
respect
advanc
age
senesc
immun
system
accumul
comorbid
condit
caus
hospit
burden
mortal
rsv
elderli
compar
season
influenza
effect
treatment
licenc
vaccin
rsv
magnitud
diseas
burden
made
develop
safe
effect
vaccin
major
global
health
prioriti
mani
decad
novel
genet
viralvector
rsv
vaccin
design
mvarsv
repres
new
promis
approach
problem
use
rsv
protein
f
tm
n
antigen
deliv
replicationdefect
adenoviru
modifi
vaccinia
viru
ankara
mva
vector
preclin
model
use
homolog
heterolog
combin
vaccin
includ
intranas
rout
found
singl
dose
intranas
intramuscular
im
vaccin
fulli
protect
lower
respiratori
tract
viral
replic
challeng
rout
also
capabl
induc
sterilis
immun
upper
respiratori
tract
importantli
immunogen
protect
efficaci
mvarsv
associ
evid
lung
immunopatholog
progress
first
trial
human
demonstr
deliveri
rsv
antigen
use
replicationdefect
viralvector
safe
capabl
robustli
boost
humor
cellular
immun
respons
healthi
adult
age
year
despit
preexist
natur
immun
rsv
report
safeti
immunogen
vaccin
healthi
older
adult
age
specif
refer
result
younger
adult
cohort
receiv
combin
vaccin
openlabel
dose
escal
phase
clinic
trial
healthi
adult
volunt
age
year
later
expand
includ
addit
healthi
adult
volunt
age
year
plan
interim
analysi
safeti
immunogen
data
younger
adult
formal
sampl
size
calcul
perform
number
volunt
studi
group
consid
standard
assess
phase
firstinman
product
safeti
toler
four
primeboost
combin
test
older
adult
select
combin
test
younger
age
cohort
preclin
data
studi
volunt
selfselect
individu
respond
open
invit
trial
provid
written
inform
consent
prior
studi
procedur
potenti
volunt
exclud
histori
signific
organ
system
diseas
known
suspect
alter
immun
system
previou
receipt
simian
adenovir
mvavector
vaccin
kind
signific
diseas
disord
present
potenti
risk
could
influenc
result
impair
particip
abil
particip
studi
detail
stab
elig
volunt
assign
studi
group
sequenti
alloc
consid
enrol
first
vaccin
visit
primari
secondari
object
respect
characteris
safeti
immunogen
primeboost
combin
vaccin
stab
end
point
clinic
trial
prospect
select
method
result
safeti
analysi
present
separ
supplementari
materi
sfig
sfig
stab
stab
secondari
endpoint
measur
immunogen
perform
observ
blind
use
randomli
gener
laboratori
identifi
collect
process
sampl
analysi
immun
respons
prespecifi
perform
describ
previous
briefli
describ
method
analysi
intracellular
stain
flow
cytometri
icsfac
analysi
describ
supplementari
materi
gener
viralvector
vaccin
mvarsv
result
preclin
evalu
describ
detail
elsewher
brief
vaccin
replicationdefect
genet
modifi
organ
engin
deliv
fusion
tm
devoid
transmembran
region
nucleocapsid
n
matrix
rsv
protein
insert
singl
synthet
codonoptimis
dna
fragment
selfcleavag
site
deriv
foot
mouth
diseas
viru
releas
tm
supernat
n
protein
remain
intracellular
delet
loci
render
adenoviru
vector
replicationdefect
mva
natur
replic
mammalian
cell
targetdos
mvarsv
use
older
adult
viral
particl
vp
plaqu
form
unit
pfu
respect
mvarsv
given
intramuscular
inject
volum
nondomin
deltoid
muscl
intranas
spray
volum
nostril
sit
posit
use
syring
attach
lma
mad
nasal
tm
needlefre
drug
deliveri
system
lma
blood
sampl
collect
heparinis
tube
assay
requir
peripher
blood
mononuclear
cell
pbmc
pbmc
isol
within
h
sampl
collect
aliquot
pbmc
immedi
use
fresh
elispot
assay
remaind
cryopreserv
recoveri
tm
cell
freez
medium
serum
sampl
obtain
centrifug
whole
blood
collect
clot
tube
cryopreserv
volunt
prime
intranas
spray
addit
nasal
sampl
obtain
three
day
later
detect
vaccin
viru
shed
pcr
sampl
collect
viral
transport
medium
analys
wuxi
apptec
inc
inocul
onto
cell
line
detect
replic
compet
incompet
adenovirus
presenc
cytopath
effect
immunofluoresc
detect
confirmatori
assay
vector
neutralis
antibodi
titr
baselin
boost
assay
use
encod
report
gene
secret
alkalin
phosphatas
seap
previous
describ
neutral
assay
neutral
titr
defin
reciproc
sera
dilut
requir
inhibit
seap
express
plaqueform
unit
rsv
strain
mix
heatinactiv
sera
rang
mixtur
incub
one
hour
facilit
neutralis
reaction
ad
confluent
layer
cell
neutralis
titr
defin
sera
dilut
plaqu
surviv
calcul
use
spearmankarb
method
antigenspecif
igg
iga
asc
detect
quantifi
dualcolour
exvivo
enzymelink
immunosorb
elispot
assay
summari
plate
coat
f
protein
antigen
fresh
pbmc
ad
plate
develop
use
antihuman
igg
iga
secondari
antibodi
respons
measur
antigenspecif
spot
per
million
pbmc
humanserum
albumin
background
subtract
posit
respons
defin
detect
spot
background
antif
igg
iga
memori
bcell
respons
measur
dualcolour
elispot
new
assay
use
younger
adult
sampl
frozen
pbmc
thaw
cultur
cpg
bioscienc
uk
pokewe
mitogen
pwm
sigma
staphylococcu
aureu
cowan
strain
sac
vwr
intern
media
concentr
cellsml
cell
harvest
dualcolour
elispot
assay
perform
describ
asc
elispot
assay
antigenspecif
ifn
produc
tcell
detect
quantifi
exvivo
elispot
assay
previous
describ
peptid
pool
consist
mainli
sequenc
amino
acid
overlap
cover
sequenc
protein
f
n
peptid
dissolv
dmso
arrang
four
pool
design
fa
n
terminu
half
f
protein
peptid
fb
c
termin
half
f
protein
peptid
n
peptid
peptid
dmso
peptid
diluent
cona
use
neg
posit
control
respect
mean
dmso
respons
sampl
identifi
cut
wherebi
individu
sampl
background
dmso
valu
spot
form
cell
per
million
pbmc
exclud
analysi
calcul
triplic
well
varianc
perform
describ
elsewher
threshold
appli
exclus
respons
consid
posit
peptid
pool
respons
spot
per
million
pmbc
b
greater
dmso
background
individu
nasal
sampl
collect
volunt
report
influenzalik
ill
stage
trial
detect
respiratori
viral
infect
use
midturbin
swab
viral
diagnost
perform
pcr
rsv
influenza
parainfluenza
rhinoviru
coronavirus
adenoviru
human
metapenumoviru
enteroviru
parechoviru
bocaviru
mycoplasma
pneumonia
analys
base
intentiontotreat
itt
popul
includ
particip
data
plan
descript
outcom
includ
hypothesi
test
use
formal
compar
statist
graph
analys
gener
use
graphpad
prism
mac
version
mac
graphpad
softwar
spss
version
mac
ibm
corpor
studi
group
descript
volunt
characterist
provid
fig
total
express
interest
receiv
initi
screen
invit
attend
physician
screen
identifi
later
enrol
elig
volunt
see
consort
sfig
vaccin
dose
administ
august
octob
allow
one
month
elaps
last
volunt
receiv
boost
vaccin
start
rsv
season
accord
public
health
england
phe
monitor
data
minimis
risk
subclin
boost
rsvspecif
immun
respons
postvaccin
period
sfig
total
schedul
visit
attend
data
use
itt
popul
analysi
visit
attend
within
postvaccin
window
specifi
trial
protocol
one
older
adult
volunt
sadli
diagnos
die
oesophag
cancer
final
visit
studi
group
singl
dose
im
mvarsv
volunt
fail
complet
trial
overal
vaccin
safe
well
toler
older
adult
studi
popul
see
supplementari
materi
sfig
sfig
stabl
stabl
one
seriou
advers
event
sae
consid
unrel
vaccin
stabl
vaccin
viru
shed
pcr
follow
studi
group
volunteerreport
influenzalik
ill
identifi
one
pcrconfirm
case
natur
rsv
infect
week
im
mvarsv
boost
volunt
group
baselin
antibodi
titr
measur
prime
repres
natur
immun
gener
repeat
exposur
sfig
adjust
baselin
immun
compar
fold
chang
antibodi
titr
dose
vaccin
peak
titr
record
younger
adult
mean
foldchang
serum
rsvneutralis
antibodi
titr
older
adult
ci
follow
im
prime
similar
magnitud
younger
adult
mean
foldchang
ci
fig
sfig
prime
im
mvarsv
singl
dose
vaccin
strategi
test
younger
adult
induc
mean
foldchang
serum
rsvneutralis
antibodi
titr
ci
compar
im
prime
well
boost
respons
observ
mvarsv
vaccin
younger
adult
studi
group
rout
prime
fail
elicit
notabl
chang
serum
antibodi
titr
mean
fold
chang
younger
older
adult
respect
observ
younger
adult
greatest
serum
rsvneutralis
antibodi
respons
note
follow
first
dose
mva
im
vaccin
subsequ
dose
im
vaccin
im
boost
fail
elicit
increment
rise
serum
antibodi
titr
older
adult
prime
group
demonstr
rise
serum
term
prime
boost
convent
term
use
indic
first
second
dose
vaccin
term
inherit
previou
adenovir
mvavector
vaccin
research
immunolog
subject
popul
alreadi
prime
repeat
natur
exposur
prime
vaccin
deliv
intramuscular
inject
im
intranas
spray
boost
vaccin
deliv
im
inject
cohort
younger
adult
studi
group
enrol
vaccin
follow
result
publish
elsewher
report
analysi
extens
trial
includ
healthi
adult
age
year
studi
group
primeboost
combin
older
adult
select
earlier
trial
data
group
nonvaccin
control
arm
serum
rsvneutralis
antibodi
titr
measur
plaquereduct
neutralis
assay
express
dilut
requir
plaqu
surviv
colour
circl
repres
adult
age
year
studi
group
empti
circl
repres
adult
age
year
studi
group
grey
circl
nonvaccin
older
adult
group
red
bar
denot
mean
left
panel
show
fold
chang
baselin
right
panel
fold
chang
preboost
rsvneutralis
antibodi
im
mvarsv
boost
mean
foldchang
serum
rsvneutralis
antibodi
titr
ci
studi
group
younger
older
adult
antibodi
titr
appear
inexor
wane
toward
prevaccin
baselin
titr
follow
peak
respons
first
dose
im
vaccin
sfig
rsv
fprotein
specif
igg
iga
immunoglobulin
produc
cell
detect
appear
low
frequenc
baselin
empti
circl
repres
adult
age
year
studi
group
grey
triangl
denot
preprim
baselin
grey
circl
nonvaccin
older
adult
group
red
bar
denot
median
dot
line
lower
limit
detect
blood
sampl
fig
measur
vaccin
found
older
adult
prime
im
develop
igg
iga
asc
respons
respons
compar
magnitud
younger
adult
receiv
vaccin
previou
year
median
spot
per
million
pbmc
igg
iga
respect
sfig
im
mvarsv
prime
detect
respons
volunt
igg
iga
median
spot
per
million
pbmc
igg
iga
respect
approxim
volunt
receiv
prime
record
measur
iggiga
asc
respons
indic
vaccin
take
volunt
howev
magnitud
respons
approxim
less
respons
observ
vaccin
given
im
inject
prime
serum
rsvneutralis
antibodi
measur
asc
respons
vaccin
consist
observ
follow
first
dose
im
vaccin
given
either
prime
boost
analysi
fspecif
iggiga
asc
respons
boost
record
notabl
respons
im
mvarsv
follow
prime
older
adult
volunt
compar
magnitud
respons
see
younger
adult
igg
iga
spot
per
million
pbmc
respect
icsfac
analysi
also
record
transient
expans
plasmablast
im
prime
sfig
assay
test
younger
older
cohort
pbmc
simultan
allow
direct
comparison
baselin
result
indic
rang
fspecif
igg
memori
bcell
frequenc
respons
detect
volunt
proport
older
adult
record
spot
per
million
pbmc
maximum
respons
younger
adult
contrast
baselin
iga
memori
bcell
frequenc
much
lower
larg
proport
volunt
sampl
could
colour
circl
repres
adult
age
year
studi
group
empti
circl
repres
adult
age
year
studi
group
red
bar
denot
median
left
panel
show
fold
chang
baselin
middl
right
panel
fold
chang
preboost
respect
detect
cell
circul
distribut
baselin
memori
bcell
frequenc
broadli
compar
younger
older
adult
sfig
follow
im
prime
mark
expans
igg
memori
bcell
later
broadli
similar
magnitud
younger
older
studi
group
receiv
vaccin
fig
sfig
im
observ
mean
geometr
fold
chang
younger
older
adult
respect
smaller
cohort
older
adult
receiv
im
mvarsv
prime
contrast
rout
fail
expand
popul
fspecif
igg
memori
bcell
circul
measur
boost
cell
popul
expand
studi
group
includ
inim
combin
vaccin
without
clear
distinct
magnitud
younger
older
adult
boost
popul
fspecif
igg
memori
bcell
appear
contract
baselin
level
observ
fspecif
iga
memori
bcell
low
baselin
frequenc
poor
expans
follow
vaccin
irrespect
rout
vector
volunt
age
icsfac
analysi
also
record
modest
expans
igg
iga
memori
bcell
im
prime
sfig
popul
rsvspecif
ifn
produc
tcell
peripher
blood
measur
ex
vivo
elispot
use
fresh
pbmc
collect
prime
boost
baselin
differ
observ
younger
older
adult
older
adult
record
fewer
spot
per
million
pbmc
compar
younger
cohort
measur
one
year
earlier
sfig
allow
differ
baselin
immun
use
foldchang
baselin
index
vaccin
immunogen
fig
sfig
found
im
prime
older
adult
reproduc
even
exceed
expans
rsvspecif
ifn
produc
tcell
peripher
blood
seen
younger
cohort
im
prime
measur
geometr
mean
foldchang
total
tcell
ifn
respons
vaccin
ex
vivo
elispot
sum
fa
fb
n
peptid
pool
background
subtract
colour
circl
repres
adult
age
year
studi
group
empti
circl
repres
adult
age
year
studi
group
grey
circl
nonvaccin
older
adult
group
top
panel
ifn
respons
vaccin
preprim
preboost
pair
postvaccin
respons
prime
boost
bottom
panel
data
express
foldchang
ifn
spot
per
million
pbmc
red
bar
denot
median
left
panel
show
fold
chang
baselin
right
panel
fold
chang
preboost
loss
sampl
volunt
studi
group
pink
dot
time
preboost
due
laboratori
error
n
younger
older
volunt
respect
im
mvarsv
prime
given
older
adult
record
geometr
mean
foldchang
prime
appreci
expans
rsvspecif
ifn
produc
tcell
peripher
blood
effect
second
dose
vaccin
measur
boost
reexpans
circul
rsvspecif
ifn
produc
tcell
popul
vector
mva
regardless
rout
prime
mvarsv
boost
respons
greatest
rise
ifn
produc
tcell
although
magnitud
mva
vectorassoci
reexpans
lower
older
adult
studi
group
geometr
mean
foldchang
younger
older
adult
respect
receiv
im
prime
younger
older
adult
respect
receiv
prime
im
homolog
boost
induc
rsvspecif
tcell
respons
expans
rel
contribut
respons
pool
peptid
fa
fb
n
result
natur
exposur
baselin
preserv
follow
vaccin
sfig
icsfac
analysi
look
pbmc
baselin
im
prime
show
respons
ifn
produc
tcell
broadli
similar
younger
older
adult
sfig
tfollicular
like
helper
cell
frequenc
marker
activ
ico
appear
substanti
alter
vaccin
older
adult
sfig
sfig
earlier
observ
younger
adult
im
rout
prime
result
similar
signific
increas
vectorneutralis
antibodi
titr
older
adult
geometr
mean
foldchang
younger
older
adult
respect
fig
sfig
rout
impact
serum
vectorspecif
immun
geometr
mean
foldchang
younger
older
adult
respect
effort
see
whether
preprim
vector
antibodi
impact
vaccin
immunogen
correl
baselin
antibodi
titr
foldchang
rsvneutralis
antibodi
fspecif
igg
antibodi
secret
cell
respons
foldchang
expans
ifn
produc
tcell
im
younger
older
volunt
appear
relationship
measur
vaccin
immunogen
safe
effect
vaccin
need
reduc
enorm
burden
emerg
hospit
admiss
death
rsv
infect
year
elderli
mvarsv
first
novel
recombin
viralvector
vaccin
candid
rsv
first
test
young
adult
studi
also
found
safe
induc
humor
cellular
rsvspecif
immun
respons
healthi
older
adult
popul
serum
fspecif
antibodi
alon
provid
partial
protect
efficaci
develop
sever
diseas
infant
shown
reduct
admiss
rsvbronchiol
monoclon
antibodi
prophylaxi
palivizumab
medimmu
high
rsvspecif
neutralis
antibodi
titr
natur
exposur
persist
later
life
rel
lower
titr
nevertheless
associ
develop
sever
diseas
elderli
baselin
antibodi
titr
volunt
trial
record
differ
year
limit
direct
comparison
natur
humor
immun
sever
observ
studi
natur
infect
found
signific
consist
quantit
qualit
deficit
antibodi
respons
mucos
immun
respons
memori
bcell
respons
increas
age
howev
greater
proport
frail
older
adult
record
rise
serum
antibodi
infect
without
concurr
rise
viral
neutralis
measur
microneutralis
assay
suggest
accumul
nonprotect
antibodi
immun
dysregul
age
addit
natur
boost
humor
immun
seem
imperfect
approxim
pcrconfirm
rsv
infect
elderli
patient
chronic
obstruct
pulmonari
diseas
symptomat
infect
associ
chang
serum
nasal
rsvspecif
antibodi
antibodymedi
protect
elderli
could
therefor
improv
vaccin
howev
vaccineinduc
antibodi
alon
may
suffici
protect
sever
lowerrespiratori
tract
diseas
mani
adult
despit
worldwid
preval
fspecif
neutralis
antibodi
surfac
express
f
protein
target
undergon
littl
tempor
evolut
suggest
rel
weak
select
pressur
younger
adult
undergo
human
stem
cell
transplant
deplet
lymphocyt
antibodi
associ
risk
progress
toward
lowerrespiratori
tract
sever
diseas
death
serum
antibodi
confer
protect
infect
appear
modul
diseas
sever
younger
adult
undergo
experiment
rsvchalleng
addit
need
gener
biolog
relev
neutralis
antibodi
parallel
restor
agerel
loss
rsvspecif
cellular
immun
vaccin
may
provid
ad
protect
need
limit
diseas
sever
elderli
first
explor
cellular
immun
respons
support
antibodi
product
mainten
clear
signal
vaccineinduc
immunogen
across
spectrum
younger
older
adult
volunt
came
fspecif
igg
iga
antibodi
secret
cell
asc
measur
vaccin
mean
fspecif
igg
asc
count
spot
per
million
pbmc
follow
im
prime
younger
older
adult
respect
compar
spot
per
million
pbmc
observ
day
follow
natur
infect
younger
older
adult
im
mvarsv
prime
older
adult
mount
compar
fspecif
asc
respons
sampl
vaccin
data
observ
natur
infect
human
experiment
rsvchalleng
vaccin
trial
consist
demonstr
transient
appear
fspecif
igg
iga
asc
peripher
circul
day
stimul
soon
disappear
cell
presum
traffic
toward
bone
marrow
mucosa
next
logic
step
look
vaccin
affect
longliv
cell
underpin
pathogenspecif
adapt
humor
immun
fspecif
igg
memori
bcell
circul
volunt
signific
proport
volunt
detect
fspecif
iga
memori
bcell
baselin
sampl
iga
respons
detect
significantli
lower
cell
frequenc
compar
rest
igg
memori
pool
dichotomi
observ
children
paediatr
healthcar
worker
control
experiment
rsvchalleng
condit
healthi
adult
also
notic
absenc
iga
memori
bcell
peripher
blood
challeng
icsfac
analysi
appear
independ
corrobor
elispot
find
plasmablast
memori
bcell
activ
togeth
absenc
iga
memori
bcell
respons
role
iga
memori
bcell
protect
rsv
unclear
intrigu
prospect
concern
effect
rsvspecif
iga
respiratori
mucosa
experiment
rsvchalleng
healthi
adult
quantiti
nasal
rsvspecif
iga
associ
risk
infect
multivari
analysi
observ
studi
describ
low
nasal
iga
rsvspecif
antibodi
titr
independ
risk
factor
rsv
infect
biolog
mucos
system
iga
requir
investig
fulli
understand
exploit
host
repertoir
rsv
immun
mvarsv
abl
robustli
expand
rsvspecif
ifn
produc
tcell
immun
older
adult
natur
infect
loss
impair
host
tcell
function
reveal
cell
provid
critic
function
restrict
diseas
sever
durat
mvarsv
boost
provid
expans
ifn
produc
tcell
independ
rout
prime
indic
ad
immunogen
boost
vaccin
case
group
confirm
natur
prime
instead
prime
suffici
support
mvavector
respons
problemat
singledos
mvavector
vaccin
trial
mvavector
respons
independ
vaccin
prime
also
observ
natur
expos
influenza
vaccin
trial
elderli
phase
ebola
vaccin
trial
trial
respons
mvavector
prime
observ
boost
adenoviru
vector
result
tcell
respons
supersed
convent
adenomva
combin
age
associ
contract
rest
rsvspecif
memori
tcell
popul
peripher
circul
expans
suppress
regulatori
tcell
rel
littl
chang
central
effector
tcell
function
repeat
season
exposur
may
rel
ineffect
maintainingboost
tcell
immun
confound
immun
senesc
elderli
particularli
desir
target
vaccin
protect
vaccineinduc
antibodi
cellular
immun
respons
blood
larg
restrict
first
dose
im
vaccin
valu
second
im
dose
ad
expans
memori
bcell
case
mvavector
expans
ifn
produc
tcell
data
rsv
infect
adult
show
correl
magnitud
rsvspecif
asc
respons
rsv
neutralis
antibodi
titr
serum
antif
igg
antibodi
titr
preclin
anim
challeng
studi
involv
prime
show
sterilis
immun
upper
lower
respiratori
tract
associ
signific
immun
respons
blood
vector
use
influenza
vaccin
mice
induc
greater
igg
antibodi
respons
bronchoalveolar
lavag
sampl
greater
ifn
tcell
respons
lung
compar
vaccin
given
intramuscular
inject
gener
greater
respons
spleen
intranas
liveattenu
influenza
vaccin
flumist
protect
efficaci
infant
indirectli
reduc
incid
influenza
elderli
although
equal
fail
elicit
substanti
immun
respons
blood
lung
laden
resid
antigenspecif
tcell
found
blood
especi
respiratori
viral
infect
influenza
rsv
adult
protect
sever
rsv
diseas
baselin
popul
resid
memori
tcell
lung
measur
serial
bronchoscopi
wash
appear
main
determin
rsv
diseas
sever
rout
younger
older
adult
could
result
desir
immun
respons
mucosa
measur
trial
mechan
behind
mucos
vaccin
bring
protect
immun
respiratori
tract
seemingli
independ
blood
respons
remain
major
focu
investig
one
obstacl
use
viralvector
vaccin
preval
serum
vectorneutralis
antibodi
potenti
abrog
vaccin
respons
describ
hiv
vaccin
trial
antiadenoviru
serotyp
neutralis
antibodi
titr
associ
impair
vaccin
immunogen
hiv
vaccin
increas
rate
hivacquisit
circumcis
men
although
associ
hivacquisit
wane
time
studi
report
adenoviru
vectorneutralis
antibodi
littl
effect
tcell
respons
mva
select
low
human
seropreval
rate
combin
potent
vitro
immunogen
although
antibodi
titr
greater
expect
us
european
popul
estim
could
detect
impact
vaccin
respons
older
adult
popul
mva
vectorspecif
immun
respons
measur
asid
specifi
exclus
criteria
potenti
remain
mvavector
immun
respons
date
far
back
childhood
smallpox
vaccin
persist
cohort
older
adult
vacciniaspecif
serum
antibodi
tcell
respons
persist
life
crossreact
earlier
smallpox
vaccin
adult
associ
small
signific
impair
ifn
respons
malaria
antigen
deliv
heterolog
primeboost
recombin
attenu
fowlpox
viru
mva
viral
vector
sever
trial
continu
use
report
success
repeat
mvavector
deliveri
suggest
mvavector
immun
may
rel
ineffect
obstacl
vaccin
older
adult
vaccin
smallpox
vaccin
childhood
becom
increasingli
infrequ
gener
popul
major
limit
trial
expans
includ
older
adult
small
cohort
vaccin
volunt
care
screen
healthi
contrast
elderli
admit
hospit
die
sever
rsv
infect
least
one
signific
comorbid
condit
infect
rate
increas
age
small
studi
popul
repres
frail
elderli
greatest
risk
develop
sever
diseas
although
direct
indirect
benefit
could
come
vaccin
healthi
older
adult
addit
clinic
trial
need
establish
whether
vaccin
remain
safe
immunogen
adult
year
signific
comorbid
immun
correl
protect
remain
elus
work
need
determin
whether
immun
respons
vaccin
especi
prime
contribut
toward
protect
sever
diseas
final
inclus
rsv
fprotein
nearli
rsv
vaccin
candid
reflect
fact
antigen
well
conserv
across
rsv
subtyp
littl
tempor
variat
target
serum
neutralis
antibodi
tcell
epitop
antibodi
direct
toward
epitop
restrict
prefus
pref
trimer
structur
rsv
f
protein
significantli
potent
confer
viral
neutralis
remain
unknown
whether
fprotein
antigen
use
mvarsv
tm
present
pref
well
stabl
postf
epitop
induct
serum
neutralis
antibodi
respons
conclus
report
first
clinic
studi
replicationdefect
viralvector
rsv
vaccin
toward
elderli
popul
need
protect
sever
rsv
diseas
mvarsv
safe
compar
data
younger
adult
receiv
vaccin
lost
potenc
boost
desir
rsvspecif
immun
respons
includ
parallel
induct
humor
cellular
immun
inclus
target
broad
tcell
immun
respons
may
prove
especi
import
protect
elderli
remain
author
declar
compet
interest
